{
  "relevance_rule": {
    "rule_text": "All abstracts that have client provided keywords",
    "approach": "keywords",
    "key_concepts": {
      "keywords": [
        "Hyperphosphatemia",
        "Parathyroid hormone",
        "Calcitriol",
        "Chronic kidney disease",
        "ESRD",
        "Phosphate binder",
        "Sevelamer",
        "sucroferric oxyhydroxide",
        "lanthanum carbonate",
        "Ferric citrate",
        "Calcium acetate",
        "Constipation",
        "Tenapanor",
        "Claudins",
        "FGF receptor",
        "Albuminuria",
        "nicotinamide",
        "vitamin D",
        "SGLT2 inhibitors",
        "canagliflozin",
        "Dapagliflozin",
        "Empagliflozin",
        "Ozempic",
        "Calcium carbonate",
        "Serum phosphate",
        "Phosphate",
        "Fibroblast growth factor 23",
        "Hemodialysis",
        "Dialysis",
        "Dialysis Outcomes and Practice Patterns Study",
        "Sodium hydrogen transport exchanger 3",
        "sodium-dependent phosphate cotransporter 2b",
        "KDIGO",
        "KDOQI",
        "Sodium",
        "Phosphorus",
        "Klotho",
        "Tight junctions",
        "Occludins",
        "Vascular calcification",
        "Bristol Stool Form Scale",
        "Interdialytic weight gain",
        "peritoneal dialysis",
        "NTX1942",
        "SLC34A2",
        "Glomerular",
        "CKD-MBD",
        "Smooth muscle calcification",
        "Oxylanthanum carbonate"
      ],
      "categories": [],
      "contextual_concepts": []
    },
    "reasoning": "This rule is explicitly marked as the relevance filter and matches abstracts containing any client provided keywords."
  },
  "priority_rules": [
    {
      "priority": "High",
      "rule_text": "Phase 2 data, Phase 3 data (including meta-analyses), real-world data (including PROs and registry data), Phosphate binders/phosphate lowering treatment; EXCLUDE Ardelyx sponsored abstracts",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 2",
          "Phase II",
          "Phase 3",
          "Phase III",
          "meta-analysis",
          "real-world data",
          "PROs",
          "patient reported outcomes",
          "registry data",
          "Phosphate binder",
          "phosphate lowering treatment"
        ],
        "categories": [
          "Clinical trial phase",
          "Real-world evidence",
          "Phosphate binder therapies"
        ],
        "contextual_concepts": [
          "meta-analyses",
          "real-world data",
          "patient reported outcomes",
          "registry data"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored"
      ],
      "reasoning": "This rule requires both keyword and context matching for phases, real-world data, and specific treatments, and must exclude Ardelyx sponsored abstracts to be mutually exclusive with the Internal priority."
    },
    {
      "priority": "Internal",
      "rule_text": "Ardelyx sponsored abstracts",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Ardelyx sponsored",
          "Ardelyx"
        ],
        "categories": [
          "Sponsorship"
        ],
        "contextual_concepts": []
      },
      "exclusions": [],
      "reasoning": "This rule is based on sponsorship and can be identified by keyword matching for 'Ardelyx sponsored' or 'Ardelyx'."
    },
    {
      "priority": "Medium",
      "rule_text": "Phase 1 data, retrospective analyses, prognostic studies, trial designs, preclinical studies; studies with trial outcomes and endpoints; other general studies; EXCLUDE Ardelyx sponsored abstracts and all High priority concepts",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 1",
          "Phase I",
          "retrospective analysis",
          "prognostic study",
          "trial design",
          "preclinical study",
          "trial outcomes",
          "endpoints"
        ],
        "categories": [
          "Clinical trial phase",
          "Study design",
          "Preclinical research"
        ],
        "contextual_concepts": [
          "general studies",
          "trial outcomes",
          "endpoints"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 2",
        "Phase II",
        "Phase 3",
        "Phase III",
        "meta-analysis",
        "real-world data",
        "PROs",
        "patient reported outcomes",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment"
      ],
      "reasoning": "This rule covers a broad set of study types and outcomes, requiring both keyword and context matching, and must exclude Ardelyx sponsored and all High priority concepts for mutual exclusivity."
    },
    {
      "priority": "Low",
      "rule_text": "All abstracts that only have mention of an indication and does not include any other data; EXCLUDE Ardelyx sponsored abstracts and all High/Medium priority concepts",
      "approach": "context",
      "key_concepts": {
        "keywords": [],
        "categories": [
          "Indication only"
        ],
        "contextual_concepts": [
          "mention of indication only",
          "no data presented",
          "no study results",
          "no endpoints",
          "no trial phase"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 1",
        "Phase I",
        "Phase 2",
        "Phase II",
        "Phase 3",
        "Phase III",
        "meta-analysis",
        "real-world data",
        "PROs",
        "patient reported outcomes",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment",
        "retrospective analysis",
        "prognostic study",
        "trial design",
        "preclinical study",
        "trial outcomes",
        "endpoints"
      ],
      "reasoning": "This rule requires semantic/contextual analysis to determine if the abstract only mentions an indication without presenting any data, and must exclude all higher priority concepts for mutual exclusivity."
    }
  ]
}